.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Chinese Patent Office
Novartis
Cipla
Merck
Farmers Insurance
Baxter
Accenture
McKesson

Generated: November 20, 2017

DrugPatentWatch Database Preview

Glycopyrrolate - Generic Drug Details

« Back to Dashboard

What are the generic sources for glycopyrrolate and what is the scope of glycopyrrolate freedom to operate?

Glycopyrrolate
is the generic ingredient in six branded drugs marketed by Watson Labs, Appco Pharma Llc, Natco Pharma Ltd, Vintage Pharms, Rising Pharms Inc, Nexgen Pharma, Sunovion Pharms Inc, Casper Pharma Llc, Luitpold, Hikma Intl Pharms, Somerset Theraps Llc, Sun Pharm Inds Ltd, Dr Reddys Labs Ltd, Par Pharm, West-ward Pharms Int, Hikma Farmaceutica, Robins Ah, Epic Pharma Llc, Teva Parenteral, Merz Pharms, Amneal Pharms Co, Abraxis Pharm, Aurolife Pharma Llc, Santos Biotech, Hospira, and Leading Pharma Llc, and is included in thirty-two NDAs. There are eighteen patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Glycopyrrolate has three hundred and twelve patent family members in forty countries and fifteen supplementary protection certificates in seven countries.

There are seventeen drug master file entries for glycopyrrolate. Thirty-two suppliers are listed for this compound. There is one tentative approval for this compound.

Pharmacology for glycopyrrolate

Drug ClassAnticholinergic
Mechanism of ActionCholinergic Antagonists

Medical Subject Heading (MeSH) Categories for glycopyrrolate

Tentative approvals for GLYCOPYRROLATE

Applicant Application No. Strength Dosage Form
u► Subscribe1MGTABLET;ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Casper Pharma Llc
ROBINUL
glycopyrrolate
TABLET;ORAL012827-001Approved Prior to Jan 1, 1982AARXYesYes► Subscribe► Subscribe► Subscribe
Luitpold
GLYCOPYRROLATE
glycopyrrolate
INJECTABLE;INJECTION089335-001Jul 23, 1986APRXNoNo► Subscribe► Subscribe► Subscribe
Sunovion Pharms Inc
UTIBRON
glycopyrrolate ; indacaterol maleate
POWDER;INHALATION207930-001Oct 29, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Natco Pharma Ltd
GLYCOPYRROLATE
glycopyrrolate
TABLET;ORAL091413-001Jun 20, 2016AARXNoNo► Subscribe► Subscribe► Subscribe
Sunovion Pharms Inc
UTIBRON
glycopyrrolate ; indacaterol maleate
POWDER;INHALATION207930-001Oct 29, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Sunovion Pharms Inc
SEEBRI
glycopyrrolate
POWDER;INHALATION207923-001Oct 29, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Sunovion Pharms Inc
UTIBRON
glycopyrrolate ; indacaterol maleate
POWDER;INHALATION207930-001Oct 29, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Sunovion Pharms Inc
SEEBRI
glycopyrrolate
POWDER;INHALATION207923-001Oct 29, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Appco Pharma Llc
GLYCOPYRROLATE
glycopyrrolate
TABLET;ORAL207201-002Jan 3, 2017AARXNoNo► Subscribe► Subscribe► Subscribe
Par Pharm
GLYCOPYRROLATE
glycopyrrolate
TABLET;ORAL040653-001Aug 31, 2006AARXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: glycopyrrolate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sunovion Pharms Inc
SEEBRI
glycopyrrolate
POWDER;INHALATION207923-001Oct 29, 2015► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: glycopyrrolate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,585,839Particles for use in a pharmaceutical composition► Subscribe
6,884,794 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets► Subscribe
7,541,022Pharmaceutical formulations for dry powder inhalers► Subscribe
7,744,855Method of making particles for use in a pharmaceutical composition► Subscribe
8,871,274Pharmaceutical formulations for dry powder inhalers► Subscribe
7,091,236Method for increasing the bioavailability of glycopyrrolate► Subscribe
8,182,791Formulations for use in inhaler devices► Subscribe
8,932,635Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation► Subscribe
9,566,239Pharmaceutical formulations for dry powder inhalers► Subscribe
9,351,928Method of making particles for use in a pharmaceutical composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: glycopyrrolate

Country Document Number Estimated Expiration
Saudi Arabia1522► Subscribe
Malaysia129384► Subscribe
Australia4859501► Subscribe
South Korea20070011466► Subscribe
South Korea101170187► Subscribe
Austria502666► Subscribe
Hungary0300593► Subscribe
Morocco28612► Subscribe
European Patent Office1663180► Subscribe
Portugal1337240► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: GLYCOPYRROLATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014 00020Denmark► SubscribePRODUCT NAME: GLYCOPYRRONIUM ELLER ET SALT DERAF, ISAER BROMIDSALTET, I KOMBINATION MED INDACATEROL ELLER ET SALT DERAF, ISAER MALEATSALTET; REG. NO/DATE: EU/1/13/862 20130919
9Finland► Subscribe
166Luxembourg► SubscribePRODUCT NAME: GLYCOPYRRONIUM OU UN DE SES SELS
1267866/02Switzerland► SubscribeFORMER REPRESENTATIVE: VOSSIUS AND PARTNER, CH
2014000025Germany► SubscribePRODUCT NAME: GLYCOPYRRONIUM ODER EIN SALZ ODER DERIVAT HIERVON (KOMPONENTE 1) UND INDACATEROL ODER EIN DERIVAT HIERVON ODER EIN SALZ VON INDACATEROL ODER EINEM DERIVAT HIERVON (KOMPONENTE 2); REGISTRATION NO/DATE: EU/1/13/862 20130919
393Luxembourg► SubscribePRODUCT NAME: GLYCOPYRRONIUM OU UN SEL DE CELUI-CI, PLUS PARTICULIEREMENT LE SEL BROMURE, COMBINE A INDACATEROL OU UN SEL DE CELUI-CI, PLUS PARTICULIEREMENT LE SEL MALEATE. FIRST REGISTRATION: 20130923
2013 00015Denmark► Subscribe
0583Netherlands► SubscribePRODUCT NAME: GLYCOPYRRONIUM EN ALLE DOOR HET BASISOCTROOI BESCHERMDE AFGELEIDEN DAARVAN; REGISTRATION NO/DATE: EU/1/12/788/001-006 20120928
3Finland► Subscribe
2013 00015Denmark► SubscribePRODUCT NAME: GLYCOPYRRONIUM ELLER ET SALT DERAF, HERUNDER GLYCOPYRRONIUMBROMID; REG. NO/DATE: EU/1/12/788/001-006 20121003
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Queensland Health
Chubb
Colorcon
Accenture
Chinese Patent Office
Farmers Insurance
Express Scripts
Teva
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot